Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation

Andrea G. Witlin, Pandu R R Gangula, Sunil J. Wimalawansa, Marjorie Grafe, James J. Grady, Chandra Yallampalli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective. We hypothesize that administration of adrenomedullin (AM), an endogenous vasodilator, will ameliorate the hypertension and growth restriction associated with chronic nitric oxide inhibition induced by L-ω nitro-L-arginine methyl ester (L-NAME) infusion in pregnant rats. Methods. Osmotic minipumps were inserted on day 14 of gestation to deliver continuously either AM, L-NAME, AM + L-NAME, or vehicle control. Systolic blood pressure was recorded daily in pregnant rats. Pregnant rats were either sacrificed on gestational days 15, 16, 17, 18, or 22, or they were allowed to deliver at term. The placentas from all of the treated groups were fixed for 24 hr in Bouin solution, sectioned, processed, embedded in paraffin, and stained with hematoxylin and eosin. The placentas were graded for the quality of fetal vessel development in the labyrinth. Results. Systolic blood pressure was increased in AM + L-NAME-treated rats. The animals that delivered in the AM + L-NAME group exhibited decreased pup weight (L-NAME and AM + L-NAME, 5.2 ± 0.1 compared with 6.4 ± 0.1 g for both AM and controls, p <0.001) and increased pup mortality (AM + L-NAME, 44.4% compared with 16.7% in L-NAME, 0% in AM and 3.1% in controls, p <0.001 AM+L-NAME compared with controls). Increased decidual necrosis, necrosis in the labyrinth, and deficient fetal vessel development in the labyrinth was identified in the placentas treated with AM + L-NAME. Conclusions. Addition of the endogenous vasodilator AM to an L-NAME-induced state of chronic NO inhibition did not ameliorate hypertension and growth restriction.

Original languageEnglish (US)
Pages (from-to)9-24
Number of pages16
JournalHypertension in Pregnancy
Volume22
Issue number1
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Adrenomedullin
Vasodilator Agents
Nitric Oxide
Pregnancy
Inner Ear
Placenta
Blood Pressure
Fetal Development
arginine methyl ester
Necrosis
Hypertension
Hematoxylin
Eosine Yellowish-(YS)
Growth
Paraffin

Keywords

  • Adrenomedullin
  • Growth restriction
  • L-NAME
  • Nitric oxide

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Internal Medicine

Cite this

Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation. / Witlin, Andrea G.; Gangula, Pandu R R; Wimalawansa, Sunil J.; Grafe, Marjorie; Grady, James J.; Yallampalli, Chandra.

In: Hypertension in Pregnancy, Vol. 22, No. 1, 2003, p. 9-24.

Research output: Contribution to journalArticle

Witlin, Andrea G. ; Gangula, Pandu R R ; Wimalawansa, Sunil J. ; Grafe, Marjorie ; Grady, James J. ; Yallampalli, Chandra. / Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation. In: Hypertension in Pregnancy. 2003 ; Vol. 22, No. 1. pp. 9-24.
@article{6b9c30d3a46e442c976bf8849824c8d1,
title = "Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation",
abstract = "Objective. We hypothesize that administration of adrenomedullin (AM), an endogenous vasodilator, will ameliorate the hypertension and growth restriction associated with chronic nitric oxide inhibition induced by L-ω nitro-L-arginine methyl ester (L-NAME) infusion in pregnant rats. Methods. Osmotic minipumps were inserted on day 14 of gestation to deliver continuously either AM, L-NAME, AM + L-NAME, or vehicle control. Systolic blood pressure was recorded daily in pregnant rats. Pregnant rats were either sacrificed on gestational days 15, 16, 17, 18, or 22, or they were allowed to deliver at term. The placentas from all of the treated groups were fixed for 24 hr in Bouin solution, sectioned, processed, embedded in paraffin, and stained with hematoxylin and eosin. The placentas were graded for the quality of fetal vessel development in the labyrinth. Results. Systolic blood pressure was increased in AM + L-NAME-treated rats. The animals that delivered in the AM + L-NAME group exhibited decreased pup weight (L-NAME and AM + L-NAME, 5.2 ± 0.1 compared with 6.4 ± 0.1 g for both AM and controls, p <0.001) and increased pup mortality (AM + L-NAME, 44.4{\%} compared with 16.7{\%} in L-NAME, 0{\%} in AM and 3.1{\%} in controls, p <0.001 AM+L-NAME compared with controls). Increased decidual necrosis, necrosis in the labyrinth, and deficient fetal vessel development in the labyrinth was identified in the placentas treated with AM + L-NAME. Conclusions. Addition of the endogenous vasodilator AM to an L-NAME-induced state of chronic NO inhibition did not ameliorate hypertension and growth restriction.",
keywords = "Adrenomedullin, Growth restriction, L-NAME, Nitric oxide",
author = "Witlin, {Andrea G.} and Gangula, {Pandu R R} and Wimalawansa, {Sunil J.} and Marjorie Grafe and Grady, {James J.} and Chandra Yallampalli",
year = "2003",
doi = "10.1081/PRG-120016789",
language = "English (US)",
volume = "22",
pages = "9--24",
journal = "Hypertension in Pregnancy",
issn = "1064-1955",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation

AU - Witlin, Andrea G.

AU - Gangula, Pandu R R

AU - Wimalawansa, Sunil J.

AU - Grafe, Marjorie

AU - Grady, James J.

AU - Yallampalli, Chandra

PY - 2003

Y1 - 2003

N2 - Objective. We hypothesize that administration of adrenomedullin (AM), an endogenous vasodilator, will ameliorate the hypertension and growth restriction associated with chronic nitric oxide inhibition induced by L-ω nitro-L-arginine methyl ester (L-NAME) infusion in pregnant rats. Methods. Osmotic minipumps were inserted on day 14 of gestation to deliver continuously either AM, L-NAME, AM + L-NAME, or vehicle control. Systolic blood pressure was recorded daily in pregnant rats. Pregnant rats were either sacrificed on gestational days 15, 16, 17, 18, or 22, or they were allowed to deliver at term. The placentas from all of the treated groups were fixed for 24 hr in Bouin solution, sectioned, processed, embedded in paraffin, and stained with hematoxylin and eosin. The placentas were graded for the quality of fetal vessel development in the labyrinth. Results. Systolic blood pressure was increased in AM + L-NAME-treated rats. The animals that delivered in the AM + L-NAME group exhibited decreased pup weight (L-NAME and AM + L-NAME, 5.2 ± 0.1 compared with 6.4 ± 0.1 g for both AM and controls, p <0.001) and increased pup mortality (AM + L-NAME, 44.4% compared with 16.7% in L-NAME, 0% in AM and 3.1% in controls, p <0.001 AM+L-NAME compared with controls). Increased decidual necrosis, necrosis in the labyrinth, and deficient fetal vessel development in the labyrinth was identified in the placentas treated with AM + L-NAME. Conclusions. Addition of the endogenous vasodilator AM to an L-NAME-induced state of chronic NO inhibition did not ameliorate hypertension and growth restriction.

AB - Objective. We hypothesize that administration of adrenomedullin (AM), an endogenous vasodilator, will ameliorate the hypertension and growth restriction associated with chronic nitric oxide inhibition induced by L-ω nitro-L-arginine methyl ester (L-NAME) infusion in pregnant rats. Methods. Osmotic minipumps were inserted on day 14 of gestation to deliver continuously either AM, L-NAME, AM + L-NAME, or vehicle control. Systolic blood pressure was recorded daily in pregnant rats. Pregnant rats were either sacrificed on gestational days 15, 16, 17, 18, or 22, or they were allowed to deliver at term. The placentas from all of the treated groups were fixed for 24 hr in Bouin solution, sectioned, processed, embedded in paraffin, and stained with hematoxylin and eosin. The placentas were graded for the quality of fetal vessel development in the labyrinth. Results. Systolic blood pressure was increased in AM + L-NAME-treated rats. The animals that delivered in the AM + L-NAME group exhibited decreased pup weight (L-NAME and AM + L-NAME, 5.2 ± 0.1 compared with 6.4 ± 0.1 g for both AM and controls, p <0.001) and increased pup mortality (AM + L-NAME, 44.4% compared with 16.7% in L-NAME, 0% in AM and 3.1% in controls, p <0.001 AM+L-NAME compared with controls). Increased decidual necrosis, necrosis in the labyrinth, and deficient fetal vessel development in the labyrinth was identified in the placentas treated with AM + L-NAME. Conclusions. Addition of the endogenous vasodilator AM to an L-NAME-induced state of chronic NO inhibition did not ameliorate hypertension and growth restriction.

KW - Adrenomedullin

KW - Growth restriction

KW - L-NAME

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=0037275806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037275806&partnerID=8YFLogxK

U2 - 10.1081/PRG-120016789

DO - 10.1081/PRG-120016789

M3 - Article

VL - 22

SP - 9

EP - 24

JO - Hypertension in Pregnancy

JF - Hypertension in Pregnancy

SN - 1064-1955

IS - 1

ER -